Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.

TSXV:APC.H - Post Discussion

Advanced Proteome Therapeutics Corporation > Advanced Proteome Therapeutics Receives Notice of Allowance
View:
Post by Betteryear2 on Apr 13, 2022 10:15pm

Advanced Proteome Therapeutics Receives Notice of Allowance

Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.

Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities